Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
Blood 2020 Sep 14;[EPub Ahead of Print], GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, JE Godwin, ML Arellano, K Sweet, A Emadi, F Ravandi, HP Erba, M Byrne, LC Michaelis, MS Topp, N Vey, F Ciceri, MG Carrabba, S Paolini, G Huls, M Jongen-Lavrencic, M Wermke, P Chevallier, E Gyan, C Récher, P Stiff, K Pettit, B Löwenberg, S Church, EK Anderson, J Vadakekolathu, MT Santaguida, MP Rettig, J Muth, T Curtis, E Fehr, K Guo, J Zhao, O Bakkacha, K Jacobs, K Tran, P Kaminker, M Kostova, E Bonvini, RB Walter, JK Davidson-Moncada, S Rutella, JF DiPersioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.